文献速递乳腺癌

cT1-2N1乳腺癌原发化疗后放疗降阶梯(RAPCHEM;BOOG 2010-03):荷兰前瞻性注册研究的5年随访结果

De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
PubMed 文献 · Lancet Oncol · 2022-08-08

这项荷兰前瞻性注册研究纳入838例cT1-2N1乳腺癌患者,按共识研究指南分为低、中、高危三组并给予相应降阶梯局部区域放疗。全组5年局部区域复发率为2.2%(95%CI 1.4-3.4),低于预设的4%假设上限,作者认为按该指南降阶梯放疗在肿瘤学上是安全的。

要点

  • 全组5年局部区域复发率2.2%(95%CI 1.4-3.4),低于预设4%的假设。
  • 低危组2.1%、中危组2.2%、高危组2.3%,各风险组5年局部区域复发率相近。
  • 遵循研究指南时,中危组5年局部区域复发率1.0%(95%CI 0.2-3.4),高危组1.4%(95%CI 0.3-4.5)。

核心结论

  • 作者认为,在按预设共识研究指南选择并治疗的cT1-2N1乳腺癌原发化疗患者中,5年局部区域复发率低于4%,支持基于局部区域复发风险降阶梯局部区域放疗在肿瘤学上是安全的。

研究设计与样本

  • 荷兰17家参与放疗中心的前瞻性注册研究(RAPCHEM,BOOG 2010-03),纳入2011年1月1日至2015年1月1日转诊的cT1-2N1乳腺癌患者。
  • 入组条件为原发化疗前影像显示1至3枚可疑淋巴结且至少1枚经病理确认,并接受原发化疗及乳腺和腋窝手术。
  • 研究指南按局部区域复发风险分低、中、高危三组并给出相应局部区域放疗推荐,放疗为生物等效剂量25次×2 Gy,可加或不加推量。
  • 研究期间荷兰普遍采用的放疗技术为正向计划或逆向计划调强放疗。
  • 838例患者纳入5年随访分析:低危组291例、中危组370例、高危组177例;主要终点为局部区域复发率,假设5年局部区域复发率低于4%(95%CI上限7.8%)。

主要发现

  • 全组5年局部区域复发率为2.2%(95%CI 1.4-3.4)。
  • 低危组5年局部区域复发率为2.1%(95%CI 0.9-4.3),中危组为2.2%(95%CI 1.0-4.1),高危组为2.3%(95%CI 0.8-5.5)。
  • 遵循研究指南时,低危组5年局部区域复发率为2.3%(95%CI 0.8-5.3),中危组为1.0%(95%CI 0.2-3.4),高危组为1.4%(95%CI 0.3-4.5)。

关键数值与推荐

  • 研究指南推荐:低危组不做胸壁放疗且不做区域放疗,中危组仅做局部放疗,高危组做局部区域放疗。
  • 放疗为生物等效剂量25次×2 Gy,可加或不加推量。
  • 预设假设为5年局部区域复发率低于4%(95%CI上限7.8%)。

临床怎么用

  • 作者认为,按该预设共识研究指南基于局部区域复发风险对选定cT1-2N1乳腺癌原发化疗患者降阶梯局部区域放疗在肿瘤学上是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary chemotherapy in breast cancer poses a dilemma with regard to adjuvant locoregional radiotherapy, as guidelines for locoregional radiotherapy were originally based on pathology results of primary surgery. We aimed to evaluate the oncological safety of de-escalated locoregional radiotherapy in patients with cT1-2N1 breast cancer treated with primary chemotherapy, according to a predefined, consensus-based study guideline. METHODS: In this prospective registry study (RAPCHEM, BOOG 2010-03), patients referred to one of 17 participating radiation oncology centres in the Netherlands between Jan 1, 2011, and Jan 1, 2015, with cT1-2N1 breast cancer (one to three suspicious nodes on imaging before primary chemotherapy, of which at least one had been pathologically confirmed), and who were treated with primary chemotherapy and surgery of the breast and axilla were included in the study. The study guideline comprised three risk groups for locoregional recurrence, with corresponding locoregional radiotherapy recommendations: no chest wall radiotherapy and no regional radiotherapy in the low-risk group, only local radiotherapy in the intermediate-risk group, and locoregional radiotherapy in the high-risk group. Radiotherapy consisted of a biologically equivalent dose of 25 fractions of 2 Gy, with or without a boost. During the study period, the generally applied radiotherapy technique in the Netherlands was forward-planned or inverse-planned intensity modulated radiotherapy. 5-year follow-up was assessed, taking into account adherence to the study guideline, with locoregional recurrence rate as primary endpoint. We hypothesised that 5-year locoregional recurrence rate would be less than 4% (upper-limit 95% CI 7·8%). This study was registered at ClinicalTrials.gov, NCT01279304, and is completed. FINDINGS: 838 patients were eligible for 5-year follow-up analyses: 291 in the low-risk group, 370 in the intermediate-risk group, and 177 in the high-risk group. The 5-year locoregional recurrence rate in all patients was 2·2% (95% CI 1·4-3·4). The 5-year locoregional recurrence rate was 2·1% (0·9-4·3) in the low-risk group, 2·2% (1·0-4·1) in the intermediate-risk group, and 2·3% (0·8-5·5) in the high-risk group. If the study guideline was followed, the locoregional recurrence rate was 2·3% (0·8-5·3) for the low-risk group, 1·0% (0·2-3·4) for the intermediate-risk group, and 1·4% (0·3-4·5) for the high-risk group. INTERPRETATION: In this study, the 5-year locoregional recurrence rate was less than 4%, which supports our hypothesis that it is oncologically safe to de-escalate locoregional radiotherapy based on locoregional recurrence risk, in selected patients with cT1-2N1 breast cancer treated with primary chemotherapy, according to this predefined, consensus-based study guideline. FUNDING: Dutch Cancer Society. TRANSLATION: For the Dutch translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. de Wild SR, de Munck L, Simons JM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022. PMID: 35952707. doi:10.1016/S1470-2045(22)00482-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。